PANEL: The Transformation of Clinical Trial Design and Operations

Transcript Now Available

Download a summary of the panel and learn from leading experts on how to plan, design and implement digital options within your trial.

Download Transcript

A panel discussion on COVID-19 as a catalyst for decentralized trial strategies

Description:

Are you actively exploring the use of hybrid or decentralized trials during this new era of drug development? Join us for an interactive panel session featuring leaders from across the industry and learn from their direct experience.

During this live stream event, panelists will explore ways in which hybrid and decentralized trials have altered traditional clinical pathways and the new landscape that sponsors, sites and patients must navigate as a result of the COVID-19 pandemic. The panelists will also highlight the challenges and opportunities with transitioning to a hybrid or decentralized trial strategy and what they would recommend for those planning to do the same. Topics will include, but are not limited to data integrity, key stakeholders, trial design, operational considerations, essential infrastructure and insights into both the role and value these types of trials will have in the future.

Register today for this informative panel discussion and increase your understanding of hybrid and decentralized trials as well as their impact to clinical research. When registering, please submit any questions or topics you’d like to have the panel discuss.

What you will learn:

Recommended strategies to digitally-enable research
Critical design and operational considerations
Challenges and opportunities created when pivoting to a hybrid or decentralized trial
Predictions for the future use and impact of hybrid and decentralized trials

Scheduling conflict and can’t attend?

No Problem.

Moderators:

Niklas Morton
Senior Vice President, Digital Services

Niklas Morton serves as senior vice president of PPD’s digital services. In this role, he oversees the operations and delivery of digitally enabled and decentralized/virtual studies, along with PPD’s robotic automation capabilities.

Prior to his most recent appointment, Morton was senior vice president of site and patient access, overseeing the site intelligence and activation, strategic feasibility, strategic site collaboration and clinical innovation teams. In that role, he led more than 1,400 professionals engaged in the identification and activation of the right research sites for each trial to access the most patients in the shortest cycle times.

Since joining PPD in 1998 as a biostatistics manager, Morton has advanced through various roles of increasing leadership and responsibility within the company. He spent nearly five years in PPD’s project management department, where he had section-head responsibility for PPD’s Europe, Middle East and Africa (EMEA) hematology/oncology group.

Brittany Erana
Vice President, Digital Solutions

Brittany Erana, M.P.M., is vice president and head of operations for PPD’s digital services. In this role, she’s responsible for setting the vision and designing the operational infrastructure and capabilities necessary to successfully deliver decentralized and digitally enabled clinical trials while upholding quality.

Brittany brings more than 15 years of broad industry experience in global research operations and strategy, digital implementation project and program delivery. Prior to joining PPD, Brittany was the global head of operations for patient-centered science and technology at another CRO where she spent nine years building out new operational capabilities and driving organizational growth across Europe and Asia-Pac.

Brittany holds a Bachelor of Arts in psychology from East Carolina University, a master’s degree in project management from Western Carolina University and a certificate in international business from University College Dublin Smurfit Business School.

Trinette Mitchell
Director, Clinical Data Integrity & Technology
Takeda Pharmaceuticals

Michelle Longmire, M.D.
Co-founder, CEO
Medable

David Coman
Chief Executive Officer at Science 37

PPD, the clinical research business of Thermo Fisher Scientific, is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.